Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 16479513.
- Also identified by PMC identifier 7109932.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a cohort study of 56 convalescent patients with severe acute respiratory syndrome (SARS), titers of immunoglobulin G (IgG) antibodies and neutralizing antibodies (NAbs) against SARS-associated coronavirus were assessed at regular intervals (at 1, 4, 7, 10, 16, and 24 months after the onset of disease) by use of enzyme-linked immunosorbent assay and neutralization assay. IgG antibody and NAb titers were highly correlated, peaking at month 4 after the onset of disease and decreasing thereafter. IgG antibodies remained detectable in all patients until month 16, and they became undetectable in 11.8% of patients at month 24. The finding that NAbs remained detectable throughout follow-up is reassuring in terms of protection provided against reinfection; however, NAb titers decreased markedly after month 16.
Medical subject headings
- Antibodies, Viral
- Severe acute respiratory syndrome-related coronavirus
- Severe Acute Respiratory Syndrome